Repository for Sepsis and Postresuscitation Samples
The objective of this study is to find a new therapeutic strategy by investigating the serial serum samples of patients with sepsis or postresuscitation state.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Repository for Samples Collected From Sepsis and Postresuscitation Patients in Emergency Intensive Care Unit|
- 1-month mortality [ Time Frame: 1 month ] [ Designated as safety issue: No ]All cause mortality within 1-month
- Hospital mortality [ Time Frame: until hospital discharge, an expected average of 2 weeks ] [ Designated as safety issue: No ]All cause mortality during hospitalization
- ICU length of stay [ Time Frame: Until ward transfer or discharge, an expected average of 7 days ] [ Designated as safety issue: No ]
- Favorable neurologic outcome [ Time Frame: at discharge, an expected average of 2 weeks and at 6-month ] [ Designated as safety issue: No ]
Favorable neurologic outcome is used for outcome measure in postresuscitation patients only.
Favorable neurologic outcome means cerebral performance category 1 and 2. This outcome is measured at discharge and 6-month after admission.
Biospecimen Retention: Samples Without DNA
Patients sera at ICU admission, day-1, day-3 and day-7 are stored in deep freezer.
|Study Start Date:||July 2006|
|Estimated Study Completion Date:||January 2016|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Adults (age over 16 years old) who have survived from nontraumatic cardiac arrest and admitted to ICU.
Adults (age over 16 years old) who satisfy the sepsis criteria (SIRS>=2 and infection is suspected for a cause) and admitted to the ICU.
|Contact: Kyung Su Kim, MD, PhDemail@example.com|
|Korea, Republic of|
|Seoul National University Hospital||Recruiting|
|Seoul, Korea, Republic of, 110-744|
|Contact: Kyung Su Kim, MD, PhD|
|Sub-Investigator: Kyung Su Kim, MD, PhD|
|Sub-Investigator: Woon Yong Kwon, MD, PhD|
|Principal Investigator: Gil Joon Suh, MD, PhD|
|Study Director:||Gil Joon Suh, Professor||Seoul National University Hospital|